These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 27884222)
61. How should we modify recommended renin-angiotensin-aldosterone system inhibition when facing the cardiorenal syndrome? Sexton DJ Circ Heart Fail; 2014 May; 7(3):536. PubMed ID: 24847129 [No Abstract] [Full Text] [Related]
62. A Reassessment of the Pathophysiology of Progressive Cardiorenal Disorders. Re RN Med Clin North Am; 2017 Jan; 101(1):103-115. PubMed ID: 27884222 [TBL] [Abstract][Full Text] [Related]
63. An Expanded View of Progressive Cardiorenal Disorders. Re RN Am J Med Sci; 2016 Jun; 351(6):626-33. PubMed ID: 27238929 [TBL] [Abstract][Full Text] [Related]
65. Angiotensin II and growth factors in the pathogenesis of diabetic nephropathy. Rincon-Choles H; Kasinath BS; Gorin Y; Abboud HE Kidney Int Suppl; 2002 Dec; (82):S8-11. PubMed ID: 12410848 [TBL] [Abstract][Full Text] [Related]
66. Pathophysiology of cardiorenal syndrome type 2 in stable chronic heart failure: workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Cruz DN; Schmidt-Ott KM; Vescovo G; House AA; Kellum JA; Ronco C; McCullough PA Contrib Nephrol; 2013; 182():117-36. PubMed ID: 23689659 [TBL] [Abstract][Full Text] [Related]
67. A possible mechanism for the progression of chronic renal disease and congestive heart failure. Re RN J Am Soc Hypertens; 2015 Jan; 9(1):54-63. PubMed ID: 25539896 [TBL] [Abstract][Full Text] [Related]
68. A mechanism for mineralocortcoid participation in renal disease and heart failure. Re RN J Am Soc Hypertens; 2015 Aug; 9(8):586-91. PubMed ID: 26101172 [TBL] [Abstract][Full Text] [Related]
69. Cardiorenal syndrome: an evolutionary point of view. Ito S Hypertension; 2012 Sep; 60(3):589-95. PubMed ID: 22753218 [No Abstract] [Full Text] [Related]
71. Role of renin-angiotensin-aldosterone system in adipose tissue dysfunction. Jing F; Mogi M; Horiuchi M Mol Cell Endocrinol; 2013 Sep; 378(1-2):23-8. PubMed ID: 22465098 [TBL] [Abstract][Full Text] [Related]
72. Cardiorenal syndrome type 5: clinical presentation, pathophysiology and management strategies from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Mehta RL; Rabb H; Shaw AD; Singbartl K; Ronco C; McCullough PA; Kellum JA Contrib Nephrol; 2013; 182():174-94. PubMed ID: 23689662 [TBL] [Abstract][Full Text] [Related]